Draft Guidance on Eprosartan Mesylate; Hydrochlorothiazide

Active ingredient: Eprosartan Mesylate; Hydrochlorothiazide

Form/Route: Tablets/Oral

Recommended studies: 2 studies

1. Type of study: Fasting
   Design: Single-dose, two way crossover in-vivo
   Strength: 600 mg/25 mg
   Subjects: Normal healthy males and females, general population
   Additional comments: Females should not be pregnant or lactating, and if applicable, should practice abstention or contraception during the study. Please include provisions for appropriate monitoring and intervention in the case of possible drug-related adverse events (e.g. subjects complaining of dizziness/lightheadedness should have blood pressure/heart rate assessed).

2. Type of Study: Fed
   Design: Single-dose, two way crossover in-vivo
   Strength: 600 mg/25 mg
   Subjects: Normal healthy males and females, general population
   Additional Comments: Please see comment above.

Analytes to measure (in appropriate biological fluid): Eprosartan and Hydrochlorothiazide in plasma

Bioequivalence based on (90% CI): Eprosartan and Hydrochlorothiazide

Waiver request of in-vivo testing: 600 mg/12.5 mg,based on (i) acceptable bioequivalence studies on the 600 mg/25 mg strength, (ii) proportional similarity of the formulations across all strengths, and (iii) acceptable in vitro dissolution testing of all strengths.

Dissolution test method and sampling times:

Please note that a **Dissolution Methods Database** is available to the public at the OGD website at [http://www.fda.gov/cder/ogd/index.htm](http://www.fda.gov/cder/ogd/index.htm). Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.

*Recommended Feb 2008*